LPLaura T. Pizzi

Laura T. Pizzi

*This is an algorithmically generated author record based on publicly available information.

Laura T. Pizzi has a total of 78 co-authors. Here are the top co-authors by number of shared publications:

  • Katherine M. Prioli

    Center for Health Outcomes, Policy and Economics, Ernest Mario School of Pharmacy, Department of Pharmacy Practice and Administration, Rutgers University, Piscataway, NJ

    6 shared publications
  • Jason J. Schafer

    Thomas Jefferson University, Philadelphia, PA, now with Global Medical & Scientific Affairs, Merck & Co., Inc, Upper Gwynedd, PA

    3 shared publications
  • Katherine M. Prioli

    Senior Research Analyst, Center for Health Outcomes, Policy, and Economics, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, New Jersey

    3 shared publications
  • Megan McCoy

    Department of Social Work, College of Social and Behavioral Sciences, Northern Arizona University, Flagstaff

    3 shared publications
  • Elizabeth Cannon-Dang

    A Department of Pharmacy Practice , Thomas Jefferson University , Philadelphia , PA , USA

    2 shared publications
  • Eric Jutkowitz

    Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, Rhode Island, USA

    2 shared publications

Latest Publications

  • Table of Contents

    by Michael J. Cangelosi, A. Chahar, Simon Eggington, Daniel Tobias Michaeli, Thomas Michaeli, Michael J. DiStefano, Joseph P. Levy, Ilina C. Odouard, Gerard F. Anderson, Michael Drummond, et al.

  • Addressing racial inequality and its effects on vaccination rate: A trial comparing a pharmacist and peer educational program (MOTIVATE) in diverse older adults

    by Katherine M. Prioli, Ayse Akincigil, Tarlan Namvar, Jocelyn Mitchell-Williams, Jason J. Schafer, Renee C. Cunningham, Lynn Fields-Harris, Megan McCoy, Ronald Vertsman, Ashley Guesnier, et al.

    BACKGROUND: The mortality, morbidity, health care utilization, and cost attributable to vaccine-preventable diseases are substantial for those aged 50 years and older. Although vaccination is the m... Plain language summary This is the first known trial that examines the effectiveness and costs of pharmacist- and peer-led educational programs designed to improve knowledge and beliefs about influ... Implications for managed care pharmacy This research highlighted the critical role of community-based education models that increase vaccination knowledge and trust among Black older adults, preven...


  • Economic Analysis of the Tailored Activity Program: A Nonpharmacological Approach to Improve Quality of Life in People Living With Dementia and their Caregivers

    by Laura T. Pizzi, Katherine M. Prioli, Eric Jutkowitz, Catherine V. Piersol, Constantine G. Lyketsos, Ilze Abersone, Katherine A. Marx, Laura N. Gitlin

    We investigated costs of delivering the Tailored Activity Program (TAP) and cost savings from two perspectives (health sector and societal) for people living with dementia (PLWD) and their caregivers (dyads) compared to attention control (AC) using data from a randomized controlled trial. The evaluation assessed intervention delivery costs and caregiver reported health care utilization. The total intervention cost of TAP was $1707/dyad versus $864/dyad for AC, and total costs over 6 months for TAP dyads as compared to AC were $1299 (CI: -$10,496, $7898) less from the healthcare perspective, and $761 (CI: -$10,133, $8611) less from the societal perspective. TAP cost savings are driven by lower use of healthcare services among participating dyads, but further analyses with larger samples is warranted to confirm its financial impact.


  • Open Access

    Serial Cervical Length Screening to Prevent Preterm Birth Among U.S. Women with a Singleton Gestation and a History of Preterm Birth: A Decision Analysis

    by Mary Smart, Neil S. Seligman, Lisa M. Gray, Katherine M. Prioli, Vincenzo Berghella, Laura Pizzi

    Background: Women with short cervix and a prior history of spontaneous preterm birth (PTB) and who are currently pregnant with a singleton gestation are considered high-risk for recurrent PTB. Serial cervical length screening can be used to identify high-risk women; those who are positively identified can be treated with either cerclage or vaginal progesterone. Objective: To evaluate the cost and effectiveness of serial cervical length screening strategies versus no screening in preventing preterm birth among women in the United States with a singleton gestation and history of preterm birth. Study Design: We developed a decision analytic model comparing serial cervical length screening plus either one of two treatment for confirmed short cervix (1. vaginal progesterone, 2. cerclage plus 17-alpha-hydroxy-progesterone caproate) compared with no screening. Costs included procedures, medications, and direct healthcare costs of delivery plus material and neonatal costs for one-year post delivery. Effectiveness was defined as the probability of successfully preventing one preterm birth at a threshold of 37 and 35 weeks. The main outcome was the difference in cost and effectiveness between the two screening methods versus no screening. Results: The cost of screening plus vaginal progesterone ($54,686) was less than the cerclage ($59,032) and no screening ($58,895) arms. At 37 weeks, the incremental effectiveness of the cerclage versus no screening arms (0.0257) was higher than the progesterone versus no screening arms (0.0063). At week 35, compared with the no screening, vaginal progesterone was less effective (-0.0036) while screening plus cerclage was slightly more effective (0.0066). Our model is most sensitive to variation in delivery and hydroxyprogesterone costs. Probabilistic sensitivity analysis indicates that VP is less costly than no screening 79.4% of the time, and cerclage is less costly than no screening 30.5% of the time. Conclusions: While serial screening with vaginal progesterone was a more cost-saving strategy, the cerclage strategy prevented more preterm births at a marginal additional cost compared to no screening.

  • Open Access

    Economic implications of FDA platelet bacterial guidance compliance options: Comparison of single‐step strategies

    by Katherine M. Prioli, Ilze Abersone, Patricia M. Kopko, Jay H. Herman, Brian Custer, Laura T. Pizzi

    BACKGROUND: Bloodborne pathogens pose a major safety risk in transfusion medicine. To mitigate the risk of bacterial contamination in platelet units, FDA issues updated guidance materials on various bacterial risk control strategies (BRCS). This analysis presents results of a budget impact model updated to include 5‐ and 7‐day pathogen reduced (PR) and large volumed delayed sampling (LVDS) BRCS.STUDY DESIGN AND METHODS: Model base‐case parameter inputs were based on scientific literature, a survey distributed to 27 US hospitals, and transfusion experts' opinion. The outputs include hospital budget and shelf‐life impacts for 5‐ and 7‐day LVDS, and 5‐ and 7‐day PR units under three different scenarios: (1) 100% LVDS, (2) 100% PR, and (3) mix of 50% LVDS ‐ and 50% PR.RESULTS: Total annual costs from the hospital perspective were highest for 100% LVDS platelets (US$2.325M) and lowest for 100% PR‐7 units (US$2.170M). Net budget impact after offsetting annual costs by outpatient reimbursements was 5.5% lower for 5‐day PR platelets as compared to 5‐day LVDS (US$1.663 vs. US$1.760M). A mix of 7‐day LVDS and 5‐day PR platelets had net annual costs that were 1.3% lower than for 100% 7‐day LVDS, but 1.3% higher than for 100% 5‐day PR. 7‐day PR platelets had the longest shelf life (4.63 days), while 5‐day LVDS had the shortest (2.00 days).DISCUSSION: The model identifies opportunities to minimize transfusion center costs for 5‐ and 7‐day platelets. Budget impact models such as this are important for understanding the financial implications of evolving FDA guidance and new platelet technologies.


  • Open Access

    Cost–Benefit Analysis of the COPE Program for Persons Living With Dementia: Toward a Payment Model

    by Laura T Pizzi, Eric Jutkowitz, Katherine M Prioli, Ember (Yiwei) Lu, Zachary Babcock, Heather McAbee-Sevick, Dorothy B Wakefield, Julie Robison, Sheila Molony, Catherine V Piersol, et al.

    Background and Objectives: There is a critical need for effective interventions to support quality of life for persons living with dementia and their caregivers. Growing evidence supports nonpharmacologic programs that provide care management, disease education, skills training, and support. This cost–benefit analysis examined whether the Care of Persons with Dementia in their Environments (COPE) program achieves cost savings when incorporated into Connecticut’s home- and community-based services (HCBS), which are state- and Medicaid-funded. Research Design and Methods: Findings are based on a pragmatic trial where persons living with dementia and their caregiver dyads were randomly assigned to COPE with HCBS, or HCBS alone. Cost measures included those relevant to HCBS decision makers: intervention delivery, health care utilization, caregiver time, formal care, and social services. Data sources included care management records and caregiver report. Results: Per-dyad mean cost savings at 12 months were $2 354 for those who received COPE with a mean difference-in-difference of −$6 667 versus HCBS alone (95% CI: −$15 473, $2 734; not statistically significant). COPE costs would consume 5.6%–11.3% of Connecticut’s HCBS annual spending limit, and HCBS cost-sharing requirements align with participants’ willingness to pay for COPE. Discussion and Implications: COPE represents a potentially cost-saving dementia care service that could be financed through existing Connecticut HCBS. HCBS programs represent an important, sustainable payment model for delivering nonpharmacological dementia interventions such as COPE.


  • Economic Analyses of Pathogen-Reduction Technologies in Blood Transfusion: A Systematic Literature Review

    by Patrick R. LaFontaine, Jing Yuan, Katherine M. Prioli, Priti Shah, Jay H. Herman, Laura T. Pizzi

    Background Technologies used in the processing of whole blood and blood component products, including pathogen reduction, are continuously being adopted into blood transfusion workflows to improve process efficiencies. However, the economic implications of these technologies are not well understood. With the advent of these new technologies and regulatory guidance on bacterial risk-control strategies, an updated systematic literature review on this topic was warranted. Objective The objective of this systematic literature review was to summarize the current literature on the economic analyses of pathogen-reduction technologies (PRTs). Methods A systematic literature review was conducted using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines to identify newly published articles in PubMed, MEDLINE Complete, and EconLit from 1 January 2000 to 17 July 2019 related to economic evaluations of PRTs. Only full-text studies in humans published in English were included in the review. Both budget-impact and cost-effectiveness studies were included; common outcomes included cost, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). Results The initial searches identified 433 original abstracts, of which 16 articles were included in the final data extraction and reporting. Seven articles presented cost-effectiveness analyses and nine assessed budget impact. The introduction of PRT increased overall costs, and ICER values ranged widely across cost-effectiveness studies, from below $US150,000/QALY to upwards of $US20,000,000/QALY. This wide range of results was due to a multitude of factors, including comparator selection, target patient population, and scenario analyses included. Conclusions Overall, the results of economic evaluations of bacterial risk-control strategies, regardless of mechanism, were highly dependent on the current screening protocols in place. The optimization of blood transfusion safety may not result in decisions made at the willingness-to-pay thresholds commonly seen in pharmaceutical evaluations. Given the critical public health role of blood products, and the potential safety benefits introduced by advancements, it is important to continue building this body of evidence with more transparency and data source heterogeneity. This updated literature review provides global context when making local decisions for the coverage of new and emerging bacterial risk-control strategies.


  • Costs of the Care for Older Persons with Dementia in their Environment (COPE) intervention when delivered through the Connecticut state Medicaid waiver program

    by Laura T Pizzi, Katherine M Prioli, Zachary Babcock, Heather McAbee‐Sevick, Dorothy Wakefield, Eric Jutkowitz, Richard H Fortinsky

    Background: The Care of Persons with Dementia in their Environments translational study (COPE‐CT) is a Connecticut‐based randomized clinical trial conducted to evaluate the efficacy of behavioral intervention (COPE) vs. usual care (UC) for persons with dementia (PwD) and their caregivers.Methods: PwD in both groups were enrolled in the Connecticut Home Care Program for Elders (CHCPE) and received a monthly home care plan. COPE, an in‐home behavioral intervention delivered by occupational therapists and an advance practice nurse, was designed to maximize PwD physical functioning and improve caregivers’ dementia management skills. Program costs included staff training and supervision (COPE), screening for program eligibility (COPE & UC), intervention delivery (COPE), travel time and mileage (COPE), supplies (COPE & UC), lab testing (COPE), and home care plan for one year pre‐enrollment to one year post‐enrollment (COPE & UC). Mean per‐dyad cost differences at 12 months vs. baseline were calculated for each group and compared using a difference‐in‐difference approach.Result: 291 PwD/caregiver dyads were randomized (145 COPE, 146 UC). Mean per‐dyad cost of COPE was $1,868 vs. $6.41 for UC, yielding an incremental difference‐in‐difference cost of $1,862/dyad for COPE. COPE delivery was the largest cost driver ($623/dyad) followed by travel time ($370/dyad) and lab testing ($316/dyad). UC costs were minimal and driven by supplies ($18.45/dyad). Both groups experienced a cost savings in the care plan at $82.06/dyad for COPE vs. $15.63/dyad for UC, but this difference was not statistically significant (p=0.5253).Conclusion: Given the lack of medical treatments for dementia, in‐home programs for PwD and their caregivers are critical. COPE represents a novel approach to dementia behavioral management and caregiver support, and the intervention costs we report inform its sustainability. Future work will examine potential cost offsets in health and social service expenditures.

  • Open Access

    Embedding caregiver support in community-based services for older adults: A multi-site randomized trial to test the Adult Day Service Plus Program (ADS Plus)

    by Laura N. Gitlin, Katherine Marx, Daniel Scerpella, Holly Dabelko-Schoeny, Keith A. Anderson, Jin Huang, Laura Pizzi, Eric Jutkowitz, David L. Roth, Joseph E. Gaugler